in-pharmatechnologist -- Genzyme has lowered 2011 financial projections after delaying the date it expects Fabrazyme production to return to normal. Manufacture of Fabrazyme (agalsidase beta) has been moved to a plant in Framingham, Massachusetts, US but production levels are yet to return to earlier levels. Genzyme had expected supply to meet demand in the first half of 2011 but has now pushed back its timeline.
